Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Sep 21st, 2023

Late-Breaking Science announced

See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.


AHA audience

LBS.01: Obesity — Novel Therapeutics and Implications for Population Health

NOTE: LBS.01 is part of the Opening General Session

 8:30-9:15 a.m. (ET) |  Saturday, Nov. 11 | Main Event I

  • Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes (SELECT) 

 LBS.02: Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome

9:45-11 a.m. (ET) | Saturday, Nov. 11 | Main Event I

  • Restrictive Versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial (MINT) 
  • Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial (ORBITA-2) 
  • DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes (DAPA-MI) 

LBS.03: Heart Failure — VADS, Kids and Money

1:30-2:45 p.m. (ET) | Saturday, Nov. 11 | Main Event I

  • Avoidance of Aspirin With Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Clinical Trial (ARIES HeartMate 3) 
  • The TEAMMATE Trial: Everolimus to Prevent Rejection in Children After Cardiac Transplantation (TEAMMATE) 
  • Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters 

LBS.04: Using Drugs, Diet and Delivery to Optimize Hypertension Outcomes

3:15-4:30 p.m. (ET) | Saturday, Nov. 11 | Main Event I

  • Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial (CARDIA-SSBP)
  • Long-Term Blood Pressure Control After Physician Optimized Postpartum Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial (POP-HT) 
  • Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension (KARDIA-1)
  • Effectiveness of Blood Pressure-Lowering Intervention on Risk of Total Dementia Among Patients With Hypertension: A Cluster-Randomized Effectiveness Trial (CRHCP) 

LBS.05: Shocking Decisions in AFib Care

8-9:15 a.m. (ET) | Sunday, Nov. 12  | Main Event I

  • Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation 
  • Abelacimab, a Novel Factor XI/XIa Inhibitor, versus Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial (AZALEA-TIMI 71) 
  • Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours: The NOAH-AFNET 6 Trial  (NOAH-AFNET 6) 
  • Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation (ARTESIA) 

 LBS.06: Future of Lipid Lowering Therapy — Novel Mechanisms and Approaches

3:30-4:45 p.m. (ET) | Sunday, Nov. 12 | Main Event I

  • Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 
  • Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial  (REMAIN-2) 
  • Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)
  • Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial 

 LBS.07: From Local to Global: Achieving Equity in Prevention

8-9:15 a.m. (ET) | Monday, Nov. 13  | Main Event I

  •  Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial (HTN Program)  
  • A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients
  • Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events (ESPRIT)
  • Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial (IMPACTS) 

LBS.08: Artificial Intelligence at the Bedside

9:45-11 a.m. (ET) | Monday, Nov. 13  | Main Event I

  • Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial  (SPEC-AI ) 
  • Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study (ORFAN) 
  • Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients 
  • Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electrocardiogram (ARISE): A Pragmatic Randomized Controlled Trial (ARISE) 

Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
More Content
Maxresdefault 65561fbdb9acc
AHA23
Watch: Scientific Sessions 2023 Day 2 | Sunday, Nov. 12
Nov 16th, 2023
Panel of speakers
AHA23
Getting to the Heart of Stroke™
Nov 15th, 2023
Hqdefault 6554fd1be4044
AHA23
Watch: Scientific Sessions 2023 | Day 1, Saturday, Nov. 11
Nov 15th, 2023
Maxresdefault 6554fad25bb7c
AHA23
Watch: Scientific Sessions 2023 Pre-Sessions Symposia & Early Career Day
Nov 15th, 2023
Audience shot
AHA23
Late-breaking science| Achieving equity in prevention
Nov 15th, 2023
audience shot
AHA23
Novel mechanisms for lipid-lowering therapy
Nov 14th, 2023
LBS 08 panelists
AHA23
Late-breaking science: AI at the bedside
Nov 14th, 2023
Lbs05 Panel Web
AHA23
Shocking decisions in AFib care
Nov 13th, 2023
Lbs04 Panel2 Web
AHA23
Drugs, diet and delivery can optimize hypertension outcomes
Nov 13th, 2023
Jane E. Freedman, MD, Ann Marie Schmidt, MD, M. Benjamin Shoemaker, MD, MSCI, J. Kevin Donahue, MD
AHA23
Established lecture to present new research developments
Nov 13th, 2023
Randi Foraker, PhD, MA, FAHA, FAMIA, Jessica L. Mega, MD, MPH
AHA23
Artificial intelligence shows promise and pitfalls
Nov 13th, 2023
Clyde W. Yancy, MD, MSc, MACC, FAHA, and Reinier Boon, PhD
AHA23
Age: Is it a number, or a biology?
Nov 13th, 2023